UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Inquiry Search clinical trials


Recruitment status Completed
Unique ID issued by UMIN UMIN000016626
Receipt No. R000019305
Scientific Title Clinical pharmacokinetic study of NIG-0392 on healthy adults.
Date of disclosure of the study information 2015/02/25
Last modified on 2016/03/25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title Clinical pharmacokinetic study of NIG-0392 on healthy adults.
Acronym Clinical pharmacokinetic study of NIG-0392 on healthy adults.
Scientific Title Clinical pharmacokinetic study of NIG-0392 on healthy adults.
Scientific Title:Acronym Clinical pharmacokinetic study of NIG-0392 on healthy adults.

Condition prevent and lower internal exposure of thyroid caused by radioiodine.
Classification by specialty
Not applicable
Classification by malignancy Others
Genomic information NO

Narrative objectives1 Examination of blood iodine kinetics and safety of NIG-0392, potassium iodine, and non-administration.
Examination of excretion amount of urinary iodine used as reference.
Basic objectives2 Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase I

Primary outcomes plasma iodine concentration
Key secondary outcomes urinary iodine concentration

Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Dynamic allocation
Institution consideration
Concealment No need to know

No. of arms 3
Purpose of intervention Prevention
Type of intervention
Interventions/Control_1 NIG-0392
Interventions/Control_2 Potassium iodine
Interventions/Control_3 Non-administration
(no medicine, water only)

Age-lower limit
20 years-old <=
Age-upper limit
40 years-old >
Gender Male
Key inclusion criteria 1) Healthy male subjects between the ages of 20 to 40 years when at informed consent.
2) Body weight between 50 and 80 kg
3) Body Mass Index between 18.5 to 25.0 kg/m2
4) Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or physical examination during screening. Some of the laboratory values e.g complete blood count etc that is out of the normal or reference range will be carefully considered by the clinical investigator.
5) Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Key exclusion criteria 1) History of hypersensitivity for any elements involved in all the investigational agents in this study
2) Tuberculosis patient
3) Hyperthyroid patient
4) Hypothyroid patient
5) Renal dysfunction
6) Myotonia congenita
7) Hyperkalemia
8) Subjects who have history of hypocomplementemic urticarial vasculitis
9) Subjects who have history of hypersensitivity for iodine contrast agent
10) Subjects who have history of dermatitis herpetiformis Duhring
11) Subjects who take upper gastrointestinal endoscopy in the term from screening test to one week after administration.
12) Serological reaction of syphilis, HBsAg, HCVAb or HIVAb positive
13) AST(GOT) or ALT(GPT): more than the reference value by screening or clinical assay before the administration in each term(excluding the case of AST or ALT value within the standard value by reexamination)
14) Subjects who have present or past history of cardiovascular system, immune system, hematologic, brain vasculature, respiratory system, digestive system, liver or renal disease
15) History of gastrointestinal tract surgery which has an effect on the drug absorption such as gastrectomy, gastrointestinal suture, or intestinal resection
16) Presence of alcohol or drug dependency
17) Subjects who need some cure for actual allergic symptom, such as asthma, pollinosis, or atopic dermatitis
18) Subjects who use other medicine in the week prior to hospitalization of 1st period or need to take other medicine during the test (including external preparation etc.)
19) Enrolled in another investigational study and took other investigational drug within 4 months(if it is a patch test, within one month)
20) Subjects who donated and/or withdrawn whole blood more than 400mL within 12 weeks, 200mL within 4 weeks, and/or blood content within 2 weeks prior to the time of consent.
21) Subjects who are judged ineligible for entry to this study by the study physician
Target sample size 48

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takashi Moritoyo
Organization The University of Tokyo Hospital
Division name Unit for Early and Exploratory Clinical Development Phase 1 Unit, Clinical Research Support Center
Zip code
Address 7-3-1 Hongo,Bunkyo-ku,Tokyo 113-8655,Japan
TEL 03-5800-9083

Public contact
Name of contact person
1st name
Middle name
Last name Takuro Yamashiro
Organization Nichi-Iko Pharmaceutical Co., Ltd.
Division name Dept. of Clinical Study
Zip code
Address 205-1 Shimoumezawa, Namerikawa City, Toyama Prefecture, Japan
TEL 076(475)5767
Homepage URL

Institute Nichi-Iko Pharmaceutical Co., Ltd.

Funding Source
Organization None
Category of Funding Organization Self funding
Nationality of Funding Organization None

Other related organizations
Co-sponsor None
Name of secondary funder(s) None

IRB Contact (For public release)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2

Institutions 東京大学医学部附属病院(東京都)

Other administrative information
Date of disclosure of the study information
2015 Year 02 Month 25 Day

Related information
URL releasing protocol
Publication of results Unpublished

URL related to results and publications
Number of participants that the trial has enrolled
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Completed
Date of protocol fixation
2015 Year 02 Month 19 Day
Date of IRB
Anticipated trial start date
2015 Year 03 Month 10 Day
Last follow-up date
2015 Year 04 Month 09 Day
Date of closure to data entry
2015 Year 05 Month 15 Day
Date trial data considered complete
2015 Year 05 Month 15 Day
Date analysis concluded
2015 Year 05 Month 15 Day

Other related information

Management information
Registered date
2015 Year 02 Month 25 Day
Last modified on
2016 Year 03 Month 25 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.